Clinical Trial Update: The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating aripiprazole with a focus on monitoring serum prolactin levels over 3 months in schizophrenia and related conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Schizophrenia
• Tardive Dyskinesia

Drugs mentioned

• Aripiprazole (Abilify) (aripiprazole)

Snippet

Sponsor: Yu-Li Hospital | Conditions: Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome | Phase 4 | Status: UNKNOWN